Safety of immune checkpoint inhibitors in a diverse patient population: a single-institution experience
Grace M Ferri, John F Murphy, Akash Oza, Alexander J B Bulteel, Wafaa Abbasi, Rachel Anderson, Mehmed Taha Dinc, Eva Gaufberg, Kayra Cengiz, Sainikhil Sontha, Janice Weinberg, Patrick Kurpaska, Yashvin Onkarappa Mangala, Matthew Kulke, Umit Tapan · 2026
Read Safety of immune checkpoint inhibitors in a diverse patient population: a single-institution experience by Grace M Ferri, John F Murphy, Akash Oza, Alexander J B Bulteel, Wafaa Abbasi, Rachel Anderson, Mehmed Taha Dinc, Eva Gaufberg, Kayra Cengiz, Sainikhil Sontha, Janice Weinberg, Patrick Kurpaska, Yashvin Onkarappa Mangala, Matthew Kulke, Umit Tapan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13365962.txt.
Description
Grace Ferri and co-workers look in 2026 at side harms of immune cancer drugs in a mixed race, mixed wealth crowd at a Boston safety net care site. Trial crowds skew narrow, so real harm rates by group were in doubt. The team charts all first line drug users from 2015 to 2022.
Of 469 patients, near one in fourteen had a drug harm. Rates ran near the same for white, Black, and Latin patients, and for state or own pay plans. No tie shows with sex, tongue, school, or smoke past. Harm calls should rest on the case, not group tags, they hold.
Catalog record
| CREATOR | Grace M Ferri, John F Murphy, Akash Oza, Alexander J B Bulteel, Wafaa Abbasi, Rachel Anderson, Mehmed Taha Dinc, Eva Gaufberg, Kayra Cengiz, Sainikhil Sontha, Janice Weinberg, Patrick Kurpaska, Yashvin Onkarappa Mangala, Matthew Kulke, Umit Tapan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11491 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |